Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial.

Objective: To explore the safety and efficacy of CF101, an A(3) adenosine receptor agonist, in patients with moderate to severe dry eye syndrome.

Design: Phase 2, multicenter, randomized, double-masked, placebo-controlled, parallel-group study.

Participants: Sixty-eight patients completed the study, 35 patients in the placebo group and 33 patients in the CF101 group.

Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial.

Objective: Adenosine exerts antiinflammatory effects via activation of the A3 adenosine receptor (A3AR), a Gi protein-associated cell-surface receptor, overexpressed in synovial tissue and peripheral blood mononuclear cells (PBMC) in patients with active rheumatoid arthritis (RA). CF101 is a highly specific orally bioavailable A3AR agonist.

Methods: This was a multicenter study, blinded to dose, designed to assess the clinical activity and safety of CF101 in active RA.

A3 adenosine receptor as a target for cancer therapy.

Targeting the A3 adenosine receptor (A3AR) by adenosine or a synthetic agonist to this receptor (IB-MECA and Cl-IB-MECA) results in a differential effect on tumor and on normal cells. Both the adenosine and the agonists inhibit the growth of various tumor cell types such as melanoma, colon or prostate carcinoma and lymphoma. This effect is specific and is exerted on tumor cells only.